一品红：子公司获得盐酸克林霉素棕榈酸酯颗粒注册证书

Group 1 - The core point of the article is that Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Clindamycin Palmitate Granules, indicating a significant development for the company [1] - The approved indication for Clindamycin is for serious infections caused by sensitive anaerobic bacteria, as well as infections caused by sensitive strains of Streptococcus, Pneumococcus, and Staphylococcus, specifically for patients allergic to penicillin or deemed unsuitable for penicillin use by a physician [1] - The product's instruction clearly includes dosage and administration guidelines for children, highlighting its applicability in pediatric medicine [1] Group 2 - Clindamycin functions as an antibacterial drug by inhibiting bacterial protein synthesis through binding to the 23S rRNA of the 50S ribosomal subunit [1]